HIV Env V3 Complex-Type N-Glycan Antibodies for Broad Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of broadly neutralizing antibodies against HIV is limited, and existing antibodies do not effectively target carbohydrate-dependent epitopes on the HIV envelope, limiting their ability to provide broad neutralization and protection against HIV infection.
Innovation Solution
Development of a new category of broadly-neutralizing anti-HIV antibodies, specifically targeting complex-type N-glycans on gp120, with unique amino acid sequences and epitope recognition, including antibodies like 10-1074 and its variants, which exhibit potent and broad reactivity against contemporary viruses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing antibodies are used to target HIV envelope, then they can provide some neutralization activity, but they fail to effectively target carbohydrate-dependent epitopes and provide broad neutralization
Solution Approach 1:
The patent applies parameter changes by modifying the antibody's epitope recognition specificity from protein-based to carbohydrate-based (complex-type N-glycans). This fundamental parameter change in the target antigen type enables the antibody to recognize a broader range of HIV strains that share conserved glycan structures, thereby achieving broad neutralization capability while maintaining reliability against contemporary viruses
Solution Approach 2:
The antibody 10-1074 and its variants exhibit universality by recognizing complex-type N-glycans that are universally present across diverse HIV-1 strains including contemporary viruses. This multi-strain recognition capability allows a single antibody to perform neutralization function across multiple viral variants, achieving both broad adaptability and consistent reliability
2Adaptability or versatility
If broadly neutralizing antibodies are developed to target diverse HIV strains, then protection against HIV infection is improved, but the understanding and characterization of these antibodies remains limited
Solution Approach 1:
The patent employs feedback by systematically characterizing the antibody's binding properties, neutralization activity, and epitope specificity through multiple assays. This detailed characterization feedback provides comprehensive information about the antibody's mechanism of action, specificity for complex-type N-glycans, and effectiveness against diverse HIV strains, thereby reducing information loss while achieving broad protection
3Reliability
If new categories of antibodies with unique amino acid sequences are developed, then potent and broad reactivity against contemporary viruses is achieved, but the complexity of antibody design and development increases
Solution Approach 1:
The patent applies copying by identifying and characterizing the unique amino acid sequences of antibody 10-1074 that confer its distinctive carbohydrate-dependent epitope recognition. By copying and analyzing these specific sequence features, particularly in the CDR regions, the patent enables rational design approaches that can replicate the potent reactivity against contemporary viruses without requiring de novo design of entire antibody molecules, thereby managing complexity
Data Source
AI summary
The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.